Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA changes Kuvan PDUFA date

BioMarin (BMRN; SWX:BMRN) said FDA pushed back the PDUFA date for an NDA

Read the full 133 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE